Department of Surgery, Brooke Army Medical Center, Ft. Sam Houston, TX, United States.
Department of Surgery, University of Texas Health Science Center, San Antonio, TX, United States.
Front Immunol. 2023 Mar 7;14:1090533. doi: 10.3389/fimmu.2023.1090533. eCollection 2023.
Checkpoint inhibitors have invigorated cancer immunotherapy research, including cancer vaccination. Classic early phase trial design and endpoints used in developing chemotherapy are not suited for evaluating all forms of cancer treatment. Peripheral T cell response dynamics have demonstrated inconsistency in assessing the efficacy of cancer vaccination. Tumor infiltrating lymphocytes (TILs), reflect the local tumor microenvironment and may prove a superior endpoint in cancer vaccination trials. Cancer vaccines may also promote success in combination immunotherapy treatment of weakly immunogenic tumors. This review explores the impact of TILs as an endpoint for cancer vaccination in multiple malignancies, summarizes the current literature regarding TILs analysis, and discusses the challenges of providing validity and a standardized implementation of this approach.
检查点抑制剂激发了癌症免疫疗法研究，包括癌症疫苗接种。经典的早期临床试验设计和终点不适用于评估所有形式的癌症治疗。外周 T 细胞反应动态在评估癌症疫苗疗效方面表现出不一致性。肿瘤浸润淋巴细胞（TILs）反映了局部肿瘤微环境，可能在癌症疫苗试验中成为一个更优越的终点。癌症疫苗也可能促进联合免疫疗法治疗弱免疫原性肿瘤的成功。本综述探讨了 TILs 作为多种恶性肿瘤癌症疫苗接种终点的影响，总结了目前关于 TILs 分析的文献，并讨论了提供该方法有效性和标准化实施的挑战。
